PriceTargets.com logo

Compugen - CGEN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.20
  • Forecasted Upside: 783.19%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$0.70 As of 03/31/2023 01:00 AM ET
▼ -0.02 (-2.77%)

This chart shows the closing price for CGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Compugen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGEN

Analyst Price Target is $6.20
▲ +783.19% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Compugen in the last 3 months. The average price target is $6.20, with a high forecast of $13.00 and a low forecast of $2.00. The average price target represents a 783.19% upside from the last price of $0.70.

This chart shows the closing price for CGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Compugen. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2023SVB LeerinkReiterated RatingOutperformLow
2/28/2023OppenheimerReiterated RatingOutperform$8.00Low
2/8/2023Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$13.00Low
11/14/2022OppenheimerLower TargetOutperform$12.00 ➝ $8.00Low
8/23/2022Truist FinancialLower TargetBuy$14.00 ➝ $4.00Low
8/8/2022JMP SecuritiesLower TargetMarket Outperform$8.00 ➝ $4.00Low
8/8/2022OppenheimerLower TargetOutperform$14.00 ➝ $12.00Low
8/5/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$2.00Low
2/25/2022OppenheimerLower TargetOutperform$17.00 ➝ $14.00Medium
2/25/2022SVB LeerinkLower TargetOutperform$16.00 ➝ $9.00Medium
11/15/2021JMP SecuritiesReiterated RatingBuy$18.00High
5/18/2021SVB LeerinkReiterated RatingBuy$16.00High
4/6/2021SVB LeerinkLower TargetOutperform$19.00 ➝ $16.00Low
3/17/2021OppenheimerReiterated RatingBuy$19.00High
8/19/2020SVB LeerinkBoost TargetOutperform$15.00 ➝ $19.00High
8/11/2020Jefferies Financial GroupReiterated RatingBuy$20.00Low
7/30/2020OppenheimerInitiated CoverageBuy$19.00High
5/26/2020JMP SecuritiesInitiated CoverageOutperform$18.00High
5/13/2020Stifel NicolausInitiated CoverageBuy$19.00High
5/7/2020SVB LeerinkInitiated CoverageOutperform$15.00High
4/28/2020SunTrust BanksBoost TargetPositive ➝ Buy$16.00 ➝ $22.00High
4/27/2020OppenheimerReiterated RatingBuy$15.00High
4/22/2020Roth CapitalInitiated CoverageBuy$28.00Medium
3/24/2020SunTrust BanksInitiated CoverageBuy$16.00High
2/21/2020Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $13.00High
1/15/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00High
2/26/2019OppenheimerSet TargetBuy$9.00High
11/7/2018OppenheimerSet TargetBuy$9.00Medium
(Data available from 4/1/2018 forward)

News Sentiment Rating

-0.62 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
11/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 7 very negative mentions
Mentions as of
12/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
3/2/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Compugen logo
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Read More

Today's Range

Now: $0.70
Low: $0.70
High: $0.74

50 Day Range

MA: $0.80
Low: $0.68
High: $0.99

52 Week Range

Now: $0.70
Low: $0.51
High: $3.57

Volume

80,683 shs

Average Volume

225,552 shs

Market Capitalization

$60.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Compugen?

The following Wall Street research analysts have issued reports on Compugen in the last year: EF Hutton Acquisition Co. I, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., StockNews.com, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for CGEN.

What is the current price target for Compugen?

5 Wall Street analysts have set twelve-month price targets for Compugen in the last year. Their average twelve-month price target is $6.20, suggesting a possible upside of 783.2%. EF Hutton Acquisition Co. I has the highest price target set, predicting CGEN will reach $13.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.00 for Compugen in the next year.
View the latest price targets for CGEN.

What is the current consensus analyst rating for Compugen?

Compugen currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGEN will outperform the market and that investors should add to their positions of Compugen.
View the latest ratings for CGEN.

What other companies compete with Compugen?

Other companies that are similar to Compugen include TScan Therapeutics, Cognition Therapeutics, Aptose Biosciences, X4 Pharmaceuticals and Gamida Cell. Learn More about companies similar to Compugen.

How do I contact Compugen's investor relations team?

Compugen's physical mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company's listed phone number is (723) 765-8585 and its investor relations email address is [email protected] The official website for Compugen is www.cgen.com. Learn More about contacing Compugen investor relations.